|
Addition of abiraterone to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Model to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Pharma (Inst); Clovis Oncology (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - ICON Clinical Research (Inst) |
|
|
Honoraria - Janssen; Sandoz; Takeda |
Consulting or Advisory Role - Cadence Research and Consulting; FirstWord; Janssen; Janssen Research & Development; Sandoz; Takeda |
Speakers' Bureau - Janssen; Janssen-Cilag |
Patents, Royalties, Other Intellectual Property - Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. Professor Dearnaley is on the Institute’s Rewards to Inventors list for abiraterone acetate. (Inst); Patent issued EP1933709B1 (location and stabilisation device) |
Expert Testimony - Vitality Life |
Travel, Accommodations, Expenses - Janssen; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Janssen; Janssen (I) |
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; AstraZeneca; Bayer; ESSA; Ferring; Janssen-Cilag; Medivation; Millennium; Novartis; Pfizer; Ventana Medical Systems; Veridex |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Ipsen; Janssen; Sanofi; Takeda; Ventana Medical Systems |
Research Funding - Arno Therapeutics (Inst); Innocrin Pharma (Inst); Janssen (Inst) |
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate. |
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Ferring; Janssen; Janssen (I); Medivation; Pfizer; Ventana Medical Systems |
Other Relationship - Institute of Cancer Research |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen; MSD Oncology; Novartis; Pfizer; Pharmacyclics; Roche/Genentech; Sanofi; Seagen |
Consulting or Advisory Role - Clovis Oncology |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; MSD |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Pharma (Inst); Clovis Oncology (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst); Sanofi (Inst) |
|
|
Honoraria - Janssen; Janssen; Lilly; Sanofi |
Research Funding - Astellas Pharma; Clovis Oncology; Janssen-Cilag; Novartis; Pfizer; Sanofi |
|
|
Consulting or Advisory Role - Inspiredx (Inst) |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Oncogenex; Pierre Fabre; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; EUSA pharma; Janssen; pfizer; Sanofi |
Speakers' Bureau - Astellas Pharma; Ferring; Janssen Oncology; Pierre Fabre; Sanofi |
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Janssen; Sanofi |